CoCrystal Pharma, Inc. announced that progress with CC-42344 for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented on December 1, 2022 at the World Antiviral Congress 2022 underway in San Diego. In November 2022 Cocrystal reported that orally administered CC-42344 showed a favorable safety profile in both the single- and multiple-ascending dose portions of the Phase 1 study. The Company is currently awaiting pharmacokinetic results from this study and plans to report topline results later this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | -0.76% | +11.43% | +13.23% |
May. 01 | Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects | CI |
Mar. 28 | Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.23% | 19.99M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- COCP Stock
- News Cocrystal Pharma, Inc.
- CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022